Tradestie Institutional Equity Comparison Engine
CELC vs PRAX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PRAX Overall Edge
PRAX Captures Institutional Edge (3โ0 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Praxis Precision Medicines, Inc. Common Stock (PRAX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CELC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PRAX at N/M Forward P/E and 0.0% operating margin (+1349.1% YoY). In options structure, CELC sits in BREAKDOWN (30th %ile IV; Dealer Gamma Walls on Pro) against PRAX sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CELC N/M vs PRAX N/M Fwd P/E
Growth & Margin Winner
PRAX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +1349.1%
Momentum & Technical Winner
PRAX
1Y -28.7% vs +73.6% ยท 52W Pos 8% vs 64%
Options & Structure Winner
PRAX
BREAKDOWN (30th %ile IV) vs CONSOLIDATION (4th %ile IV)
CELC
NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$61.31
-4.75% 1D
Market Cap
$3.2B
1M Return
+8.36%
1Y Return
-28.71%
Forward P/E
N/M
Unified AI Score
39.7 / 100
SELL
Tech 25.0
Fund 43.0
Flow 59.0
Mom 64.0
PRAX
NASDAQ
Praxis Precision Medicines, Inc. Common Stock
Pharmaceutical Preparations
$309.08
-5.81% 1D
Market Cap
$9.1B
1M Return
+27.85%
1Y Return
+73.56%
Forward P/E
N/M
Unified AI Score
34.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 71.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CELC -28.71%
PRAX +73.56%
Spread: +102.27 pp (PRAX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CELC TTM Op. Margin: 0.0%
PRAX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELC vs PRAX. Trailing 12-month operating profitability (CELC 0.0% vs PRAX 0.0%) and valuation multiples (CELC N/M vs PRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CELC | PRAX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2B | $9.1B | Larger Scale | PRAX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +1349.1% | Higher Growth | PRAX |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1192.9% | -44.8% | Higher ROE | PRAX |
| 52-Week Range Position Momentum | 8% ($54โ$151) | 64% ($160โ$393) | Stronger Trend | PRAX |
| Beta / 30D Volatility Risk Regime | 1.28ฮฒ ยท 60% Vol | 1.79ฮฒ ยท 93% Vol | Lower Realized Risk | CELC |
| Unified Institutional Score Composite Signal | 39.7 / 100 (SELL) | 34.6 / 100 (SELL) | Higher Composite | CELC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CELC vs PRAX Buy Guide
CELC
BREAKDOWN
136d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
30th %ile
IV Regime
Balanced (25thโ60th %ile)
PRAX
CONSOLIDATION
67d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CELC nor PRAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.